RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Inflammatory Myopathy
Dermatomyositis
Anti-Synthetase Syndrome
Immune-Mediated Necrotizing Myopathy
Juvenile Dermatomyositis
Juvenile Polymyositis
Juvenile Idiopathic Inflammatory Myopathy (JIIM)
Juvenile Myositis

Interventions

BIOLOGICAL: CABA-201 following preconditioning with fludarabine and cyclophosphamide

Sponsor

Cabaletta Bio